VFA
KYMR icon

Values First Advisors’s Kymera Therapeutics KYMR Stock Holding History

Values First Advisors’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,296
Closed -$61.3K – 263
2024
Q3 		$61.3K Buy
+1,296
New +$57.2K 0.03% 217

Other funds holding KYMR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Values First Advisors's KYMR Position: Q4 2024 in Review

Values First Advisors sold out of Kymera Therapeutics (KYMR) in Q4 2024, closing a stake of 1,296 shares — an estimated $61.3K sold.

Values First Advisors first reported a position in KYMR in Q3 2024 and held it in 1 quarter. The position peaked at $61.3K in Q3 2024. 180 funds tracked by Wall St. Rank hold KYMR as of Q4 2024.

  • Values First Advisors reported no remaining Kymera Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Values First Advisors sold 1,296 Kymera Therapeutics shares in Q4 2024, an estimated $61.3K.
  • Values First Advisors first reported a position in Kymera Therapeutics in Q3 2024 and held it in 1 quarter.
  • Values First Advisors's Kymera Therapeutics position peaked at $61.3K in Q3 2024.
  • 180 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q4 2024.

Based on Values First Advisors's 13F filing for Q4 2024, filed 29 Jan 2025.